|Title:||Guidance on ambulatory blood pressure monitoring: A statement from the HOPE Asia Network||Authors:||Kario, Kazuomi
Huynh, Van Minh
Soenarta, Arieska Ann
Sogunuru, Guru Prasad
Tay, Jam Chin
Teo, Boon Wee
|Keywords:||ambulatory blood pressure monitoring; blood pressure control; clinical practice; guidelines; hypertension;ambulatory blood pressure monitoring; blood pressure control; clinical practice; guidelines; hypertension||Issue Date:||Mar-2021||Publisher:||WILEY||Journal Volume:||23||Journal Issue:||3||Start page/Pages:||411||Source:||Journal of clinical hypertension (Greenwich, Conn.)||Abstract:||
Hypertension is an important public health issue due to its association with a number of serious diseases, including cardiovascular disease and stroke. The importance of evaluating hypertension taking into account different blood pressure (BP) profiles and BP variability (BPV) is increasingly being recognized, and is particularly relevant in Asian populations given the specific features of hypertension in the region (including greater salt sensitivity and a high rate of nocturnal hypertension). Ambulatory BP monitoring (ABPM) is the gold standard for diagnosing hypertension and assessing 24-hour BP and provides data on several important parameters that cannot be obtained using any other form of BP measurement. In addition, ABPM parameters provide better information on cardio- and cerebrovascular risk than office BP. ABPM should be used in all patients with elevated BP, particularly those with unstable office or home BP, or who are suspected to have white-coat or masked hypertension. ABPM is also an important part of hypertension diagnosis and monitoring in high-risk patients. ABPM needs to be performed using a validated device and good practice techniques, and has a role both in hypertension diagnosis and in monitoring the response to antihypertensive therapy to ensure strict BP control throughout the 24-hour period. Use of ABPM in clinical practice may be limited by cost and accessibility, and practical education of physicians and patients is essential. The ABPM evidence and practice points in this document are based on the Hypertension Cardiovascular Outcome Prevention and Evidence (HOPE) Asia Network expert panel consensus recommendations for ABPM in Asia.
|URI:||https://scholars.lib.ntu.edu.tw/handle/123456789/592773||ISSN:||1524-6175||DOI:||10.1111/jch.14128||metadata.dc.subject.other:||angiotensin receptor antagonist; antihypertensive agent; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; antihypertensive agent; atherosclerosis; blood pressure monitoring; blood pressure regulation; blood pressure variability; brain hemorrhage; cardiovascular risk; circadian rhythm; cognitive defect; comorbidity; coronary artery disease; cost control; diastolic blood pressure; diastolic dysfunction; disease association; drug efficacy; health care access; heart left ventricle hypertrophy; high risk patient; human; low risk patient; masked hypertension; microangiopathy; prevalence; prognosis; reimbursement; Review; sensitivity and specificity; sleep disordered breathing; systolic blood pressure; telemedicine; treatment response; white coat hypertension; Asia; blood pressure; blood pressure measurement; hypertension; Antihypertensive Agents; Asia; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitoring, Ambulatory; Humans; Hypertension
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.